Advertisement

Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson’s disease

  • B. Piallat
  • A. Benazzouz
  • A. L. Benabid
Conference paper
Part of the 6th International Winter Conference on N eurodegeneration book series (NEURAL SUPPL, volume 55)

Summary

Several evidences showed that glutamate can be implicated in the degenerative process of dopaminergic neurons in Parkinson’s disease. The treatment with NMDA antagonists have been shown to induce a neuroprotective effect in animal models of this disease. As subthalamic nucleus neurons send direct glutamatergic projections to the substantia nigra, we studied the effects of kainic acid lesion of this nucleus on the degeneration of dopaminergic neurons induced by microinjection of 6-hydroxydopamine in the striatum of rat done one week after the first lesion. Animals were killed 15 days after the injection of 6-hydroxydopamine. Immunohistochemical study showed that lesion of the subthalamic nucleus can prevent the degeneration of substantia nigra dopaminergic somata when carried out one week prior to 6-hydroxydopamine injection in the striatum. Nevertheless neurochemical results showed that this lesion did not antagonize the striatal 6-hydroxydopamine-induced dopamine depletion in the striatum 15 days after 6-hydroxydopamine injection.

Keywords

Kainic Acid Subthalamic Nucleus NMDA Antagonist High Frequency Stimulation Lesion Side 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aziz TZ, Peggs D, Sambrook MA, Crossman AR (1991) Lesion of the subthalamic nucleus for the alleviation of protection protection protection 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 6: 288–292.PubMedCrossRefGoogle Scholar
  2. Benazzouz A, Gross C, Féger J, Boraud T, Bioulac B (1993) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 5: 382–389.PubMedCrossRefGoogle Scholar
  3. Benazzouz A, Piallat B, Pollak P, Benabid AL (1995) Responses of substantia nigra pars reticulata and globus pallidus complex to high frequency stimulation of the subthalamic nucleus in rats: electrophysiological data. Neurosci Lett 189: 77–80.PubMedCrossRefGoogle Scholar
  4. Benazzouz A, Boraud Th, Féger J, Burbaud P, Bioulac B, Gross Ch (1996) Alleviation of experimental hemiparkinsonism by high frequency stimulation of the subthalamic nucleus in primate: A comparison with L-dopa treatment. Mov Disord 11: 627–632.PubMedCrossRefGoogle Scholar
  5. Bergman H, Wichmann T, Delong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436–1438.PubMedCrossRefGoogle Scholar
  6. Bergman H, Wichmann T, Karmon B, DeLong MR (1994) The primate subthalamic nucleus. IL Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72: 507–520.PubMedGoogle Scholar
  7. Hammond C, Deniau JM, Rizk A, Féger J (1978) Electrophysiological demonstration of an excitatory subthalamonigral pathway in the rat. Brain Res 151: 235–244.PubMedCrossRefGoogle Scholar
  8. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Lebas JF, Broussole E, Perret JE, Benabid AL (1995a) Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. The Lancet 345: 91–95.CrossRefGoogle Scholar
  9. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Broussolle JE, Perret J, Benabid AL (1995b) Bilateral subthalamic nucleus stimulation for severe Parkinson’s disease. Mov Disord 10: 672–674.PubMedCrossRefGoogle Scholar
  10. Marshall JF, O’Dell SJ, Weihmuller FB (1993) Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity. J Neural Transm 91: 241–254.CrossRefGoogle Scholar
  11. Miller WC, De Long MR (1987) Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB, Jayaraman A (eds). The basal ganglia II, Advances in Behavioral Biology 32 Plenum, New York pp 415–427.Google Scholar
  12. Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR (1989) Neural mechanisms underlying parkinsonian symptoms base upon regional uptake of 2-deoxyglucose in monkeys exposed to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Neurosci 32: 213–226.CrossRefGoogle Scholar
  13. O’Dell SJ, Weihmuller FB, Marshall JF (1992) MK-801 prevents methamphetamineinduced striatal dopamine damage and reduces extracellular dopamine overflow in neurotoxins and neurodegenerative disease. Ann NY Acad Sci 648: 317–319.PubMedCrossRefGoogle Scholar
  14. Parent A, Hazrati L (1995) Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Rev 20: 128–154.PubMedCrossRefGoogle Scholar
  15. Piallat B, Benazzouz A, Benabid AL (1996) Subthalamic nucleus lesion in rat prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioral and immunohistochemical studies. Eur J Neurosci 8: 1408–1414.PubMedCrossRefGoogle Scholar
  16. Robledo P, Féger J (1990) Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data. Brain Res 518: 47–54.PubMedCrossRefGoogle Scholar
  17. Sonsalla PK, Nicklas WJ, Heikkila RE (1989) Role for excitatory amino acids in methamphetamine induced nigrostriatal dopaminergic toxicity. Science 243: 398–400.PubMedCrossRefGoogle Scholar
  18. Sonsalla PK, Riordan DE, Heikkila RE (1991) Competitive and non competitive antagonists at NMDA receptors protect against methamphetamine-induced dopaminergic damage in mice. J Pharmacol Exp Ther 256: 506–512.PubMedGoogle Scholar
  19. Storey E, Hyman BT, Jenkins B, Bouillet E, Miller JM, Rosen BR, Beal FM (1992) MPP+ produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 58:1975–1978.PubMedCrossRefGoogle Scholar
  20. Turski L, Bressler K, Rettig KJ, Löschmann PA, Watchel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by NMDA antagonists. Nature 349: 414–418.PubMedCrossRefGoogle Scholar
  21. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU (1992) MK-801 prevents MPTP-induced parkinsonism in primates. J Neurochem 59: 133–739.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1999

Authors and Affiliations

  • B. Piallat
    • 1
  • A. Benazzouz
    • 1
  • A. L. Benabid
    • 1
  1. 1.Laboratoire de Neurobiologie Préclinique, INSERM U.318CHUGrenoble Cedex 09France

Personalised recommendations